With INJ price predictions in 2025 receiving renewed attention, Injective is currently trading within the important $6-$7 multi-year support zone, an area that has caused strong reversals many times in history. With bullish fundamentals, ETF expectations, and a major network upgrade ahead, Injective appears positioned for one of its most significant rebounds to date.
Multi-year support for INJ: historic starting point for a big rally
With INJ price hovering around $7.81 today, Injective is located in the support range that has consistently served as a long-term reversal zone. The previous interaction with the $6-$7 zone has produced a sharp multi-week rally, and traders are now expecting a similar reaction as the overall market stabilizes.
The technical structure also supports this outlook. The INJ price chart shows price compression at the lower end of the long-term range, consistent with a descending wedge that has been active since August 2024. On the other hand, historically, each touchpoint on this trend line triggers an upward move, creating optimism that a breakout towards $21 by the end of the year is still achievable.
Fundamental strengths: Injection lead development and network activities
Beyond the price movement, Injective’s fundamentals continue to strengthen. It currently ranks #1 in weekly code commits across all blockchains, indicating top-level development activity. With over 1.5 billion transactions processed, Injective also ranks 10th in the world in total transactions based on annual data.
This level of growth indicates growing adoption of the network and growing developer trust in the ecosystem. Increased activity often precedes active price discovery, reinforcing the positive outlook for INJ price forecasts in 2025.
ETF speculation and mainnet upgrades build bullish momentum
Institutions are also showing strong interest. In October, 21Shares filed an S-1 application with the SEC to launch the first-ever INJ ETF. The application will be reviewed once the U.S. government resumes full regulatory operations, and the chances of approval appear promising.
ETF approval will unlock new liquidity channels and significantly expand market access for injective cryptos. This reflects the ETF inflows that boosted Bitcoin and Ethereum earlier this year.
Meanwhile, Injective is preparing to release Altria Mainnet Upgrade (IIP 583) within the next five days. This upgrade was seen as a major step forward and amplified the community’s expectations that momentum was decisively shifting towards bullishness.
Technical indicators show accumulation before expansion
Although long-term indicators appear constructive, some technical tools are still showing mixed signals. An RSI near 37.50 indicates further cooling in the market and could lead to a fall into an even deeper discount zone around 30. MACD and AO remain subdued, suggesting that consolidation is still underway.
However, the Chaikin Money Flow of 0.14 indicates that positive inflows are increasing, suggesting that accumulation is already occurring below the surface. If momentum turns bullish, INJ price USD could revisit $21, extend towards $44, and retest the $52 ATH in 2026.
As these catalysts align, INJ price predictions for 2025 continue to strengthen, making injectives one of the hottest recovery strategies in the market.
Trust CoinPedia:
CoinPedia has been providing accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by an expert panel of analysts and journalists following strict editorial guidelines based on EEAT (Experience, Expertise, Authority, and Trustworthiness). All articles are fact-checked against trusted sources to ensure accuracy, transparency, and authenticity. Our review policy ensures unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely and up-to-date information on everything cryptocurrencies and blockchain, from startups to industry giants.
Investment Disclaimer:
All opinions and insights shared represent the author’s own views on current market conditions. Please do your own research before making any investment decisions. Neither the author nor the publication is responsible for your financial choices.
Sponsors and advertising:
Sponsored content and affiliate links may appear on our site. Ads are clearly marked and our editorial content is completely independent of our advertising partners.